BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(7 sites)

United States

Mayo Clinic Arizona, Phoenix, Arizona

Beth Israel Deaconess Medical Center, Boston, Massachusetts

Brigham and Women's Hospital, Boston, Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts

Mayo Clinic, Rochester, Minnesota

Washington University, St Louis, Missouri

Memorial Sloan Kettering Cancer Center, New York, New York